

Saskatchewan Health Authority - Saskatoon Area AntibioGram 2018

LONG TERM CARE PATIENTS - All Isolates (including Urinary isolates)

January 1, 2018 - December 31, 2018

% Susceptible

# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalixin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Gentamicin	Tobramycin	Vancomycin
GRAM-NEGATIVE BACTERIA																								
<i>Escherichia coli</i> ¹	753	38		77	94		59	84		69	69	100	100					54		70	95	87	85	
<i>Klebsiella pneumoniae</i> ¹	260	R		80	93		50	95		51	50	100	100					84		77	36	81	80	
<i>Klebsiella oxytoca</i> ‡	18	R		100	100		R	100		89	89	100	100					100		100	88	100	100	
<i>Pseudomonas aeruginosa</i>	69	R			96						97	94						78		R	R	88	100	
<i>Proteus mirabilis</i> ¹	175		92	99	100		94	97		99	100	100	100					80		94	R	95	96	

# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalixin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Gentamicin ³	Tobramycin	Vancomycin
GRAM-POSITIVE BACTERIA																								
<i>Staphylococcus aureus</i> , all																								
- methicillin-susceptible (MSSA)	58		100				100							56		53	100	58	65	98	100	83		100
- methicillin-resistant (MRSA)	42	R	R	R	R	R	R	R	R	R	R	R	R	54		R	100	R	R	78	100	67		100
<i>Enterococcus faecalis</i> , all	235		100			R	R	R	R	R	R					R	31	64	50		99	77		100
<i>Enterococcus faecium</i> , all	32		33			R	R	R	R	R	R					R	85	R	R		33	100		44

R - intrinsically resistant

‡ Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH adult in/out patient antibiogram data

¹ 6.4% of combined *E. coli*, *K. pneumoniae*, *P. mirabilis* isolates were ESBL (extended spectrum beta-lactamase) positive

² these organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

³ susceptibility to gentamicin in gram positive organisms refers to combination synergy treatment only